FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039521880> ?p ?o ?g. }

• W2039521880 endingPage "748" @default.
• W2039521880 startingPage "740" @default.
• W2039521880 abstract "Previous Phase II studies using the combination of mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) in the treatment of metastatic breast carcinoma have shown this regimen to be active and well tolerated. In this randomized Phase II study, the authors compared the NFL regimen with a standard CMF regimen in the first-line therapy of patients with metastatic breast carcinoma.One hundred twenty-eight women receiving their first chemotherapy for metastatic breast carcinoma were entered into this randomized study. Sixty-four patients were treated with NFL: mitoxantrone 12 mg/m2 IV on Day 1; leucovorin 300 mg IV over 30-60 minutes on Days 1, 2, and 3, immediately preceding administration of 5-fluorouracil; and 5-fluorouracil 350 mg/m2 IV bolus on Days 1, 2, and 3. Sixty-four patients received CMF: cyclophosphamide 600 mg/m2 IV on Day 1; methotrexate 40 mg/m2 IV on Day 1; and 5-fluorouracil 600 mg/m2 IV on Day 1. Both regimens were repeated at 21-day intervals; responding patients received at least 8 courses.Patients treated with NFL had a higher response rate than patients treated with the CMF regimen (45% vs. 26%, respectively; P = 0.021). Median duration of response was 9 months with NFL and 6 months with CMF (P = 0.10); 11 patients had long responses (>12 months) with NFL versus 4 patients with CMF (P = 0.06). Median survival was similar for both groups. Both regimens were well tolerated, with infrequent Grade 3 or 4 toxicities.NFL is an active, well-tolerated regimen for the treatment of metastatic breast carcinoma; it produced a higher response rate than the CMF regimen used in this study. Although more intense CMF regimens or regimens containing doxorubicin would likely increase the response rate, they would almost certainly do so with the consequence of greater toxicity as compared with NFL. NFL is an excellent initial palliative treatment option for elderly patients or patients who have exhibited poor tolerance for other chemotherapy regimens." @default.
• W2039521880 created "2016-06-24" @default.
• W2039521880 creator A5041060500 @default.
• W2039521880 creator A5057644746 @default.
• W2039521880 creator A5065917441 @default.
• W2039521880 creator A5067138875 @default.
• W2039521880 creator A5083274876 @default.
• W2039521880 date "1997-02-15" @default.
• W2039521880 modified "2023-09-27" @default.
• W2039521880 title "Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma" @default.
• W2039521880 cites W1723350107 @default.
• W2039521880 cites W1811085086 @default.
• W2039521880 cites W1836115940 @default.
• W2039521880 cites W1843618725 @default.
• W2039521880 cites W1846747462 @default.
• W2039521880 cites W1861752845 @default.
• W2039521880 cites W1872096120 @default.
• W2039521880 cites W1888433797 @default.
• W2039521880 cites W1897371354 @default.
• W2039521880 cites W1940165440 @default.
• W2039521880 cites W1946038024 @default.
• W2039521880 cites W1955744924 @default.
• W2039521880 cites W1960713055 @default.
• W2039521880 cites W1992636214 @default.
• W2039521880 cites W1992651372 @default.
• W2039521880 cites W2003071454 @default.
• W2039521880 cites W2016232187 @default.
• W2039521880 cites W2032566866 @default.
• W2039521880 cites W2036742389 @default.
• W2039521880 cites W2044522732 @default.
• W2039521880 cites W2045764934 @default.
• W2039521880 cites W2051536649 @default.
• W2039521880 cites W2081392398 @default.
• W2039521880 cites W2133243551 @default.
• W2039521880 cites W2157800681 @default.
• W2039521880 cites W2181090862 @default.
• W2039521880 cites W2227235589 @default.
• W2039521880 cites W2253920138 @default.
• W2039521880 cites W2254049575 @default.
• W2039521880 cites W2254397276 @default.
• W2039521880 cites W2264224358 @default.
• W2039521880 cites W2296462761 @default.
• W2039521880 cites W4255152173 @default.
• W2039521880 cites W2313308602 @default.
• W2039521880 doi "https://doi.org/10.1002/(sici)1097-0142(19970215)79:4<740::aid-cncr11>3.0.co;2-#" @default.
• W2039521880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9024712" @default.
• W2039521880 hasPublicationYear "1997" @default.
• W2039521880 type Work @default.
• W2039521880 sameAs 2039521880 @default.
• W2039521880 citedByCount "7" @default.
• W2039521880 crossrefType "journal-article" @default.
• W2039521880 hasAuthorship W2039521880A5041060500 @default.
• W2039521880 hasAuthorship W2039521880A5057644746 @default.
• W2039521880 hasAuthorship W2039521880A5065917441 @default.
• W2039521880 hasAuthorship W2039521880A5067138875 @default.
• W2039521880 hasAuthorship W2039521880A5083274876 @default.
• W2039521880 hasConcept C126322002 @default.
• W2039521880 hasConcept C141071460 @default.
• W2039521880 hasConcept C2776694085 @default.
• W2039521880 hasConcept C2776755627 @default.
• W2039521880 hasConcept C2780456651 @default.
• W2039521880 hasConcept C2780923524 @default.
• W2039521880 hasConcept C2781059491 @default.
• W2039521880 hasConcept C2781413609 @default.
• W2039521880 hasConcept C43376680 @default.
• W2039521880 hasConcept C71924100 @default.
• W2039521880 hasConcept C90924648 @default.
• W2039521880 hasConceptScore W2039521880C126322002 @default.
• W2039521880 hasConceptScore W2039521880C141071460 @default.
• W2039521880 hasConceptScore W2039521880C2776694085 @default.
• W2039521880 hasConceptScore W2039521880C2776755627 @default.
• W2039521880 hasConceptScore W2039521880C2780456651 @default.
• W2039521880 hasConceptScore W2039521880C2780923524 @default.
• W2039521880 hasConceptScore W2039521880C2781059491 @default.
• W2039521880 hasConceptScore W2039521880C2781413609 @default.
• W2039521880 hasConceptScore W2039521880C43376680 @default.
• W2039521880 hasConceptScore W2039521880C71924100 @default.
• W2039521880 hasConceptScore W2039521880C90924648 @default.
• W2039521880 hasIssue "4" @default.
• W2039521880 hasLocation W20395218801 @default.
• W2039521880 hasLocation W20395218802 @default.
• W2039521880 hasOpenAccess W2039521880 @default.
• W2039521880 hasPrimaryLocation W20395218801 @default.
• W2039521880 hasRelatedWork W1989798994 @default.
• W2039521880 hasRelatedWork W1990916592 @default.
• W2039521880 hasRelatedWork W1996935284 @default.
• W2039521880 hasRelatedWork W2039521880 @default.
• W2039521880 hasRelatedWork W2066636228 @default.
• W2039521880 hasRelatedWork W2080573457 @default.
• W2039521880 hasRelatedWork W2095042174 @default.
• W2039521880 hasRelatedWork W2361899087 @default.
• W2039521880 hasRelatedWork W2419372162 @default.
• W2039521880 hasRelatedWork W4234620304 @default.
• W2039521880 hasVolume "79" @default.
• W2039521880 isParatext "false" @default.
• W2039521880 isRetracted "false" @default.
• W2039521880 magId "2039521880" @default.
• W2039521880 workType "article" @default.